跳至主要内容
临床试验/NCT05360628
NCT05360628已完成早期 1 期

A Phase I, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic Interactions Between D-0120 and Allopurinol in Healthy Adult Subjects

InventisBio Co., Ltd1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
入组人数
20
试验地点
1
主要终点
Type, incidence, severity and attribution of AEs.

研究概览

简要总结

Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects between the ages of 18-55
  • Required evaluation by Investigator for screening and enrollment
  • Agreement and compliance with the study and follow-up procedures

排除标准

  • Significant medical history or current comorbidly determined by the Investigator.
  • Pregnant or nursing women

研究组 & 干预措施

D-0120 plus Allopurinol

Experimental

D-0120 dosing followed by Allopurinol and combination treatment

干预措施: D-0120 in combination with Allopurinol (Drug)

Allopurinol plus D-0120

Experimental

Allopurinol dosing followed by D-0120 and combination treatment

干预措施: D-0120 in combination with Allopurinol (Drug)

结局指标

主要结局

Type, incidence, severity and attribution of AEs.

时间窗: 14 days

Evaluation of safety between D-0120 and Allopurinol

Plasma concentration of D-0120 and Allopurinol

时间窗: 14 days

Evaluation of exposure between D-0120 and Allopurinol

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验